Priority setting for health in emerging markets

Journal of Comparative Effectiveness Research

Volumn 2, Issue 3, 2013, Pages 283-291

  Glassman, Amanda ^a   Giedion, Ursula ^b   McQueston, Kate ^a  

^a CENTER FOR GLOBAL DEVELOPMENT   (United States)

^b NONE

Author keywords

comparative effectiveness; cost effectiveness; health technology assessment; low income country; middle income country

Indexed keywords

COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; HEALTH SERVICES RESEARCH; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; INCOME; MARKETING; MEDICAL RESEARCH; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; PRIORITY JOURNAL; REVIEW;

COMPARATIVE EFFECTIVENESS RESEARCH; DEVELOPING COUNTRIES; HEALTH CARE SECTOR; HEALTH EXPENDITURES; HEALTH PLANNING; HEALTH PRIORITIES; HEALTH SYSTEMS AGENCIES; HUMANS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84886943505     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.12     Document Type: Review

References (44)

1. Stafinski T, Menon D, Philippon DJ, McCabe C. Health technology funding decision-making processes around the world: the same, yet different. Pharmacoeconomics 29(6) 475-495 (2011).
2. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 25(6), 467-479 (2007).
3. Mohara A, Youngkong S, Velasco RP, et al. Using health technology assessment for informing coverage decisions in Thailand. J. Compar. Effect. Res. 1(2), 137-146 (2012).
4. Teerawattananon Y, Russell S. A difficult balancing act: policy actors' perspectives on using economic evaluation to inform health-care coverage decisions under the universal health insurance coverage scheme in Thailand. Value Health 11, S52-S60 (2008).
5. Al-Aqeel S. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon. Outcomes Res. 4, 177-184 (2012).
6. Gavaza P, Shepherd M, Shcherbakova N, Khoza S. The state of health economic evaluation research in Russia. J. Pharm. Health Serv. Res. 1(3), 113-121 (2010).
7. Gavaza P, Rascati K, Oladapo AO, Khoza S. The state of health economic research in South Africa: a systematic review. Pharmacoeconomics 30(10), 925-940 (2012).
8. Jha P, Laxminarayan R. Choosing Health: An Entitlement For All Indians. Center for Global Health Research, ON, Canada (2009).
9. Reddy KS, Patel V, Jha P, et al. Towards achievement of universal health care in India by 2020: a call to action. Lancet 377, 760-768 (2011).
10. Yang B, Bae E, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff. (Millwood) 27(1), 179-187 (2008).
11. Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr. Ther. Res. 69(3), 268-285 (2008).
12. Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in Nigeria: a systematic review. Pharmacoeconomics 28(7), 539-553 (2010).
13. Glassman A, Chalkidou K. Priority-Setting in Health: Building Institutions for Smarter Public Spending. The Center for Global Development, Washington, DC, USA (2012).
14. Global Health Expenditure Database. WHO Geneva, Switzerland (2012).
15. Gottret PE, Schieber GJ. Health Transitions, Disease Burdens, and Health Expenditure Patterns. In: Health Financing Revisited: a Practitioner's Guide. World Bank, Washington, DC, USA (2006).
16. Plumridge H. Rising nations are no remedy for big pharma. Wall Street Journal. 25th May 2010.
17. Eggleston K. Pharmaceutical policy in China. Health Aff. 27(4), 1042-1050 (2008).
18. OECD Health Data 2012. OECD (Ed.). Paris, France (2012).
19. Abdelhamid A, Shemilt I. Glossary of terms. In: Evidence-Based Decisions and Economics. Wiley-Blackwell, Oxford, UK (2010).
20. Chisholm D, Evans D. Improving Health System Efficiency as a Means of Moving twards Universal Coverage. World Health Report 2010, Geneva, Switzerland (2010).
21. Jamison D, Breman JG, Measham AR, et al. Disease Control Priorities in Developing Countries (2nd Edition). World Bank, Washington, DC, USA (2006).
22. Shankar R, Hickson S. Guiding principles for providing effective access to medicines in emerging markets. Presented at: ISPOR 15th Annual European conference. Berlin, Germany, 3-7 November 2012.
23. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373(9659), 240-249 (2009).
24. Giedion U, Muñoz A, Avila A. [Series of Technical Notes on Health Prioritization Processes: Introduction to the Series of Explicit Prioritization in Health]. Inter-American Development Bank, Washington, DC, USA (2012).
25. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low-and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 71(11), 903-917 (2009).
26. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics 29(9), 781-801 (2011).
27. Mulligan JA, Walker D, Fox-Rushby J. Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base. Cost Eff. Resour. Alloc. 4, 7 (2006).
28. Chaikledkaew U, Lertpitakpong C, Teerawattananon Y, Thavorncharoensap M, Tangcharoensathien V. The current capacity and future development of economic evaluation for policy decision-making: a survey among researchers and decision-makers. Value Health 12(Suppl. 3), S31-S35 (2009).
29. Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific Region. Value Health 11, S137-S155 (2008).
30. Iglesias CP, Drummond MF, Rovira J; NEVALAT Project Group. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int. J. Technol. Assess. Health Care 21(1), 1-14 (2005).
31. Congreso de la República de Colombia. Diario Oficial No. 47.758 de 2 de Julio de 2010. Congreso de la República de Colombia, Bogota, Colombia (2010).
32. Pan American Health Organization. Health Technology Assessment And Incorporation Into Health Systems. Presented at: 28th Pan American Sanitary Conference, 64th Session Of The Regional Committee. WHO, Washington, DC, USA, 17-21 September 2012.
33. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund Report of the market dynamics and commodities ad-hoc committee. Presented at: Twenty Third Board Meeting. Geneva, Switzerland, 11-12 May 2011.
34. Towse A, Devlin N, Hawe E, Garrison L. The evolution of HTA in emerging market health care systems: analysis to support a policy response. www.tree4health.org/distancelearning/sites/www.tree4health.org.distancelearning/ files/readings/Towse%20Devlin%20Hawe%20 Garrison.pdf (Accessed 18 January 2013)
35. INAHTA. Global networking for effective healthcare. www.inahta.net (Accessed 14 May 2012)
36. Health expenditure, public (percentage of total health expenditure). http://data.worldbank.org/indicator/SH. XPD.PUBL/countries/1W-XT-BR-RU-IN-TR-ID? display=graph (Accessed 31 July 2012)
37. Advancing the responsible use of medicines: applying levers for change. www.responsibleuseofmedicines.org/wp-content/uploads/2012/09/ IIHI-Ministers-Report-170912-Final.pdf (Accessed 18 January 2013)
38. The WHO Essential Medicines List (EML): 30th anniversary, 2007. www.who.int/medicines/events/fs/en/index. html (Accessed 31 July 2012)
39. CHOosing Interventions that are Cost Effective (WHO-CHOICE). www.who.int/choice/costs/CER-thresholds/en/index.html (Accessed 3 August 2012)
40. Health Technology Assessment (HTA) Guideline in Croatia. ISPOR 13th Annual European Congress. www.ispor.org/congresses/prague1110/ ReleasedPresentations/HTA-Guidelines-in-CEE-Slides.pdf (Accessed 18 January 2013)
41. Pinto Masis D, Ortega OP, Verano RD (2008). [The Economic Burden of Gaucher Disease and Fabry in Colombia]. Fedesarrollo (August). www.fedesarrollo.org.co/wp-content/uploads/2011/08/Carga-Econ-Gaucher-y-Fabry-D- Pinto.pdf (Accessed 23 February 2013)
42. FUNGSI BAHAGIAN. Ministry of Health Malaysia. http://medicaldev.moh.gov. my/v2/modules/xt-conteudo/index.php?id=4 (Accessed 18 January 2013)
43. Mittermayer R. Agency for Quality and Accreditation in Health. www.haigekassa.ee/uploads/userfiles/file/PATH/Presentations/Agency%20for%20 Q%20and%20Accred%20in%20HC.pdf (Accessed 18 January 2013)
44. Infraestructura management and technology. http://portal.ccss.sa.cr/ portal/page/portal/GIT/Tab3 (Accessed 18 January 2013)